Invention Grant
- Patent Title: Inhibitor compounds
- Patent Title (中): 抑制剂化合物
-
Application No.: US14426549Application Date: 2013-09-09
-
Publication No.: US09409907B2Publication Date: 2016-08-09
- Inventor: Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
- Applicant: Cancer Research Technology Limited
- Applicant Address: GB London
- Assignee: Cancer Research Technology Limited
- Current Assignee: Cancer Research Technology Limited
- Current Assignee Address: GB London
- Agency: Foley Hoag LLP
- Agent David P. Halstead
- Priority: GB1216017.2 20120907
- International Application: PCT/GB2013/052360 WO 20130909
- International Announcement: WO2014/037750 WO 20140313
- Main IPC: A01N43/90
- IPC: A01N43/90 ; A61K31/519 ; C07D471/00 ; C07D487/00 ; C07D471/04 ; C07D401/14 ; C07D413/14 ; C07D401/04 ; C07D405/04 ; C07D519/00
Abstract:
The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Public/Granted literature
- US20150239884A1 INHIBITOR COMPOUNDS Public/Granted day:2015-08-27
Information query
IPC分类:
